This is a sources sought notice to identify qualified small businesses capable of operating the NIH Major Histocompatibility Complex (MHC) Tetramer Core Facility, which synthesizes and distributes specialized immunological reagents to the global research community. The work involves providing a production facility, a distribution and tracking system, website maintenance, and program management, requiring an estimated 9 FTEs annually. The anticipated contract is a cost-reimbursement, term type agreement with a one-year base period and six one-year options, for a total possible performance period of seven years starting approximately March 21, 2027. The performance location is not specified in the provided description. Interested small businesses must submit a tailored capability statement, not exceeding five pages, demonstrating their relevant experience, key personnel qualifications, and technical capabilities.